Economic Aspects Of Lung Cancer

The costs of systemic treatment of lung cancer are rising rapidly due to the use of new and targeted substances. Increases in survival will further add to this development. This explains the exemplary health economic relevance of the treatment of lung cancer, which can be analyzed using various economic methods and instruments. From epidemiologic and economic perspectives, prevention should be given highest priority but the formation of health political and social opinion is not yet completed. Valid evidence on the roles of screening interventions can be expected in the next years. In this article legal, institutional and cooperative approaches within the health care system to address this problem are discussed.